Patents Issued in February 1, 2022
  • Patent number: 11234991
    Abstract: Assay methods for determining purity of a sample of a sterol are provided. These methods include providing an HPLC eluent including a sterol, other compounds related to the sterol and a mobile volatile phase; generating an aerosol of liquid droplets from the HPLC eluent; drying the liquid droplets to obtain residue particles of the sterol; contacting the residue particles of the sterol with an ion stream which applies a size-dependent electrical charge to each of the residue particles to generate an electrical signal and measuring the electrical signal to determine the purity of the sterol in the sample. The sterol can be OXY133 or OXY133 monohydrate.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: February 1, 2022
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Roger E. Harrington, Jerbrena C. Jacobs
  • Patent number: 11234992
    Abstract: The disclosure provides for therapies and methods to treat atherosclerosis and/or hyperlipidemia, and complications resulting therefrom, with compositions that comprise therapeutically effective amounts of one or more human milk oligosaccharides.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: February 1, 2022
    Assignee: The Regents of the University of California
    Inventors: Philip Gordts, Ariane Pessentheiner, Lars Bode
  • Patent number: 11234993
    Abstract: The present invention provides an alcohol extract of Ajuga taiwanensis Nakai ex Murata exhibits significant effects on inhibiting the senescence in human WI-38 lung fibroblasts and human dermal fibroblasts. Moreover, the alcohol extract of A. taiwanensis is able to suppress the expression of the cofilin-1, a protein involved in actin dynamics and cell morphology and found to be increased in senescent cells. Suppression effect of cell senescence by this herb extract is more efficient in mild concentration without over-inhibition of cell viability and growth.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: February 1, 2022
    Assignee: NATIONAL YANG-MING UNIVERSITY
    Inventors: Yi-Jang Lee, Yun-Lian Lin, Chung-Sheng Huang, Cheng-Han Tsai, Chun-Yuan Chang, Bing-Ze Lin, Yuan-Heng Tu, Wei-Hsiang Hsu, Pin-Ho Lo
  • Patent number: 11234994
    Abstract: The present disclosure relates to RNA interference (RNAi) reagents for treatment of oculopharyngeal muscular dystrophy (OPMD), compositions comprising same, and use thereof to treat individuals suffering from OPMD or which are predisposed thereto.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: February 1, 2022
    Assignee: Benitec Biopharma Limited
    Inventors: David Suhy, Michael Graham, Capucine Trollet, Alberto Malerba, John George Dickson
  • Patent number: 11234995
    Abstract: The present invention can provide a nucleic acid medicine which has a higher effect and a more prolonged effect of inhibiting the expression of ?-synudein can be provided. Disclosed is the oligonucleotide or a pharmacologically acceptable salt thereof, the oligonucleotide containing at least one nucleoside structure represented by Formula (I): (where each of Base and A are defined substituent or structure), can bind to an ?-synudein gene, has activity for inhibiting expression of the ?-synudein gene, and is complementary to the ?-synudein gene, and the oligonucleotide has a length of twelve to twenty bases.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: February 1, 2022
    Assignees: OSAKA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY, NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION
    Inventors: Masayuki Nakamori, Hideki Mochizuki, Satoshi Obika, Takanori Yokota, Tetuya Nagata, Yuya Kasahara
  • Patent number: 11234996
    Abstract: Described herein are methods for treating fibrosis, e.g., kidney fibrosis, using agents that target Secreted Modular Calcium-binding protein 2 (SMOC2).
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: February 1, 2022
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Vishal S. Vaidya, Casimiro Gerarduzzi
  • Patent number: 11234997
    Abstract: The invention relates to topical formulations comprising: a galactooligosaccharide; 0.01% to 10% w/w xylitol; and a pharmaceutically or cosmetically acceptable carrier. The invention also relates to use of the formulations, and methods for their preparation.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: February 1, 2022
    Inventors: Andrea Zanardi, Alessandra Cercaci, Ivan Montaldo
  • Patent number: 11234998
    Abstract: The present invention comprises chitosan materials and methods of using carbonic acid for aqueous solubilization of neutralized or pre-treated chitosan gels and provides, among other things, substantially acid salt free composition native final forms without requiring subsequent acid salt elution. The invention includes chitosan-based solid and semi-solid material forms, optionally reinforced with chitosan fibers, such as powders, fibers, films, matrices, sponges, implants, scaffolds, fillers, and hydrogels. Native final forms are produced from chitosan powder solubilized in an aqueous acidic solution, processed to form a high pH hydrated chitosan gel precipitate material that is then neutralized by water washing and re-solubilized substantially to chitosan solution using carbonic acid.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: February 1, 2022
    Assignee: Tricol Biomedical, Inc.
    Inventors: Simon McCarthy, Barbara McGrath, Sam Kuhn, Jess Kimball, Michael Stolten, Amanda Bennett
  • Patent number: 11234999
    Abstract: It relates to a topical composition comprising specific amounts of: a) a hyaluronic acid or a pharmaceutically or veterinary acceptable salt thereof, b) one or more adhesive agents, and c) a non-absorbable antibiotic; to delivery devices comprising it; and to its uses in medicine, in particular, in the treatment and/or prevention of mucosal lesions; in the prevention of postpolypectomy syndrome; as adjuvant therapy to mechanical treatments in gastrointestinal perforations, and as sealant treatment in surgical anastomoses and leaks or fistulas in gastrointestinal tract.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: February 1, 2022
    Assignees: FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL, CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED
    Inventors: Vicente Maria Lorenzo-Zúñiga García, Ramon Bartolí Solé, Jaume Boix Valverde
  • Patent number: 11235000
    Abstract: The invention provides CaO2 nanoparticles having a pH-responsive coating for use in a method of adjuvant therapy of hypoxic tumour cells or tissues. The nanoparticles find particular use in enhancing cancer therapies that depend on oxygen to exert their effect, such as photodynamic therapy (PDT), sonodynamic therapy (SDT), and radiotherapy. The invention also provides pharmaceutical compositions containing the coated CaO2 nanoparticles, together with at least one photosensitiser, sonosensitiser, or radiosensitiser and, optionally, at least one pharmaceutical carrier or excipient.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: February 1, 2022
    Assignee: UNIVERSITY OF ULSTER
    Inventors: Anthony Mchale, John Callan, Yingjie Sheng
  • Patent number: 11235001
    Abstract: Provided are a RUNX inhibitor which binds to a RUNX-binding sequence on DNA and thus inhibits the binding of a RUNX family member to the sequence; an antitumor agent comprising the RUNX inhibitor; and an antiallergic agent comprising the RUNX inhibitor.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: February 1, 2022
    Assignee: KYOTO UNIVERSITY
    Inventors: Hiroshi Sugiyama, Yasuhiko Kamikubo
  • Patent number: 11235002
    Abstract: Therapeutically-active compositions and formulations for treating pain, pruritus, irritation, inflammation, and tissue damage due to the irritation and inflammation, and therapeutically-active compositions and formulations for wound management, including wounds that are at high risk for infection. Strontium and beta hydroxybutyrate based compositions and formulations which can be topically applied.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: February 1, 2022
    Assignee: Galleon Labs LLC
    Inventors: Gary S. Hahn, Siva Gudi
  • Patent number: 11235003
    Abstract: The present invention relates to a topical pharmaceutical preparation for treating an inflammatory skin condition, preferably a condition associated with ischemia, comprising a supernatant of a physiological solution obtainable by cultivating peripheral blood mononuclear cells (PBMCs) or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: February 1, 2022
    Assignee: APOSCIENCE AG
    Inventor: Hendrik Jan Ankersmit
  • Patent number: 11235004
    Abstract: Embodiments described herein relate to compositions including genetically modified CAR cells and uses thereof for treating cancer. Some embodiments of the present disclosure relate to compositions and methods for T cell response enhancement and/or CAR cell preparation. For example, a method may include obtaining cells comprising a CAR and culturing the cells in the presence of an agent that is recognized by the extracellular domain of the CAR.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: February 1, 2022
    Assignee: Innovative Cellular Therapeutics Holdings, Ltd.
    Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, Zhao Wu
  • Patent number: 11235005
    Abstract: This invention relates to a method for repairing and reconstructing a damaged or non-functional muscle, in particular to a method and a tool kit using in vitro primed motor endplate-expressing muscle progenitor cells (MPCs) to promote innervation of the damaged or non-functional muscle using an agent without any genetic manipulation. This method is particularly useful for repairing or reconstructing damaged or non-functional head and neck muscles, and urinary detrusor bladder muscle.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: February 1, 2022
    Assignee: Purdue Research Foundation
    Inventor: Stacey L. Halum
  • Patent number: 11235006
    Abstract: An inhibiting or alleviating agent for amyloid beta (A?)-induced damage in hippocampus including an extract from inflamed tissues inoculated with vaccinia virus. Also relates to the use of the extract from inflamed tissues inoculated with vaccinia virus in the preparation of an agent for inhibiting or alleviating A?-induced damage in hippocampus.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: February 1, 2022
    Assignees: NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventor: Jun Liu
  • Patent number: 11235007
    Abstract: Described herein are compositions composed of micronized placental components and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions are also described herein.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: February 1, 2022
    Assignee: MiMedx Group, Inc.
    Inventors: Brenda S. Morse, Somaly Sith, Randall Spencer, Steven Ray, John Daniel, Robert Tofe
  • Patent number: 11235008
    Abstract: The present application relates to nutritional compositions comprising lactic acid-producing bacteria.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: February 1, 2022
    Assignee: Ganeden Biotech, Inc.
    Inventors: Sean Farmer, David Keller, Andrew R. Lefkowitz
  • Patent number: 11235009
    Abstract: The present invention provides a method of improving the phenomenon of the glomerular sclerosis and mononuclear leukocyte infiltration around renal tissues, and increasing the renal function by administering the probiotic bacterium of a Parabacteroides goldsteinii to a subject in need to inhibit the occurrence of chronic kidney disease. The Parabacteroides goldsteinii can also effectively modulate the gene expression level of MCP-1, IL-1?, COL3A, COL6A1, ACAA2, PPAR-?, CPT1, and PGC-1? in kidney tissues to reduce kidney inflammation and renal fibrosis and enhance the mitochondria activity of kidney cells. Therefore, the Parabacteroides goldsteinii of the present invention can be utilized in pharmaceutical compositions for inhibiting or treating chronic kidney diseases.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: February 1, 2022
    Assignee: MULTISTARS BIOTECHNOLOGY COMPANY LIMITED
    Inventors: Po-I Wu, Chih-Jung Chang, Yu-Ling Tsai
  • Patent number: 11235010
    Abstract: A composition is described that includes at least one lactic acid bacteria, preferably Lactobacillus johnsonii LA1 NCC 533 (deposit number CNCM I-1225) in an acceptable carrier. Also described, is use of the composition in the treatment and/or prevention of a dermatological disease, preferably atopic dermatitis.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: February 1, 2022
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Carine Rosignoli
  • Patent number: 11235011
    Abstract: Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: February 1, 2022
    Assignee: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD.
    Inventors: Guangmei Yan, Xiao Xiao, Jun Hu, Kai Li, Jiankai Liang, Yuan Lin, Haipeng Zhang, Suizhen Lin
  • Patent number: 11235012
    Abstract: Formulations comprising a combination of red propolis and red algae, e.g., L. calcareum, as active ingredients, and methods of treatment using the same are provided herein. In various embodiments, the formulation may be in the form of, e.g., an aqueous solution or suspension, an ingestible solid or liquid form, or a topical preparation, and may be used to treat a variety of diseases and conditions responsive to the combination.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: February 1, 2022
    Inventor: Walter A. Bretz
  • Patent number: 11235013
    Abstract: The present disclosure relates to a dissolvable thin oral tape, film or strip or segment thereof composition or device, including a film former, at least one cannabinoid, menthol, caffeine and vitamins, where the menthol component can be a stabilized menthol composition comprising menthol and at least one menthol stabilizer compound including undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: February 1, 2022
    Inventors: Babak Ghalili, Emma Ghalili
  • Patent number: 11235014
    Abstract: Provided herein are custom therapeutic compositions combining select Chinese herbs and strains of Cannabis, methods of making the compositions, and methods of using the composition for treatment of headache pain.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: February 1, 2022
    Inventor: Artashes Mirzatuny
  • Patent number: 11235015
    Abstract: An antiviral traditional Chinese medicine composition, a preparation method therefor and a pharmaceutical application thereof. The composition uses Herba Taraxaci, Radix Stemonae, Pseudobulbus Cremastrae Seu Pleiones, Radix Puerariae, Rhizoma Atractylodis Macrocephalae, and Radix Cynanchi Atrati as main active pharmaceutical ingredients, may also optionally and additionally use Cortex Lycii Radicis and Cortex Mori as active pharmaceutical ingredients, and is prepared into a pharmaceutically acceptable dosage form according to needs. The medicine composition is effective against influenza A virus, H1N1, H7N7 and H9N2 viruses, Zika virus, dengue virus I, dengue virus II, and Chikungunya virus.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: February 1, 2022
    Inventor: Hongzhang Jia
  • Patent number: 11235016
    Abstract: The use of Salvia haenkei extract is described as a re-epithelizing and cicatrizing agent in the treatment of tissue lesions. Pharmaceutical compositions comprising Salvia haenkei extract and suitable pharmaceutically acceptable excipients for use in the treatment of tissue lesions are also disclosed.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: February 1, 2022
    Assignee: Altergon SA
    Inventors: Andrea Alimonti, Andrea Maria Giori, Monica Montopoli, Jessica Cadau
  • Patent number: 11235017
    Abstract: The use of Salvia haenkei extract as an active agent in the treatment of dermatological diseases is described. Also described are pharmaceutical compositions comprising Salvia haenkei extract and suitable pharmaceutically acceptable excipients, for use in the treatment of dermatological diseases.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: February 1, 2022
    Assignee: Altergon SA
    Inventors: Andrea Alimonti, Andrea Maria Giori, Monica Montopoli, Jessica Cadau
  • Patent number: 11235018
    Abstract: The present invention provides a pharmaceutical composition for preventing or treating cancer, a food composition for enhancing immune functions, and a pharmaceutical composition for preventing or treating cachexia. The composition of the present invention provides effects of further inhibiting the growth of tumors, increasing immunological activity, and suppressing cachexia caused by tumors. In addition, the composition of the present invention can obtain a synergistic effect when co-administered with an existing anticancer drug.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: February 1, 2022
    Assignee: OKCHUNDANG CO., LTD.
    Inventors: Sae Kwang Ku, Seong Min Ku, Tae Hun Ku, Chui Jong Jung, Gyung Yun Beik, Jin Gi Shin, Sang Soo Lee, Jeong Gyun Seo, Chil Surk Yoon, Xian Li
  • Patent number: 11235019
    Abstract: Some embodiments comprise dietary supplements for treating or preventing traveler's diarrhea comprising: (a) about 1000 mg green tea extract comprising at least 90% (w/w) catechins; (b) about 4 g partially hydrolyzed guar gum (PHGG); (c) about 100 mg L-theanine; and (d) about 5 g non-sugar sweetener, wherein the sweetener does not contain a polyol. Some embodiments comprise dietary supplement for treating or preventing traveler's diarrhea comprising: (a) from about 250 mg to about 1,500 mg green tea extract comprising at least 90% (w/w) catechins; (b) from about 1 g to about 8 g partially hydrolyzed guar gum (PHGG); and (c) from about 15 mg to about 250 mg L-theanine.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: February 1, 2022
    Assignee: ARTESA LLC
    Inventor: William E. Driessen
  • Patent number: 11235020
    Abstract: Methods and compositions are provided for treating or preventing a neurological disease or disorder using an inhibitor of Glyoxalase 1 (GLO1). In some embodiments, the inhibitor is a small molecule. In certain embodiments, the disease or disorder is a sleep disorder, a mood disorder such as depression, epilepsy, an anxiety disorder, substance abuse, substance dependence or substance such as an alcohol withdrawal syndrome.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: February 1, 2022
    Inventors: Abraham Palmer, Margaret Distler, Katherine M. J. McMurray
  • Patent number: 11235021
    Abstract: A solid antimicrobial hydrogel comprising a first amphiphilic component. The first amphiphilic component, in its chemically cross-linked state, being a lyotropic liquid crystal and having an ordered nanostructure of hydrophobic and hydrophilic domains, the composition further comprising an antimicrobial agent being covalently attached to at least one of the hydrophilic or hydrophobic domains.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: February 1, 2022
    Assignee: AMFERIA AB
    Inventors: Anand Kumar Rajasekharan, Saba Atefykta, Martin Andersson
  • Patent number: 11235022
    Abstract: The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: February 1, 2022
    Assignee: Cedars-Sinai Medical Center
    Inventors: Mark Pimentel, Ruchi Mathur, Christopher Chang
  • Patent number: 11235023
    Abstract: The present invention relates to pharmaceutical aerosols comprising a ?-hairpin peptidomimetic of formula cyclo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-), or a pharmaceutically acceptable salt thereof, having inhibitory activity against human neutrophil elastase. It further relates to solid or liquid pharmaceutical compositions and kits for preparing and administering such aerosols. The invention can be used for the prevention, management or treatment of pulmonary diseases, such as alpha-1 antitrypsin deficiency (AATD), cystic fibrosis (CF), non-cystic fibrosis bronchiactasis (NCFB), or chronic obstructive pulmonary disease (COPD), or infections, or diseases, or conditions of the lungs, being mediated by or resulting from human neutrophil elastase activity.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: February 1, 2022
    Assignee: POLYPHOR AG
    Inventors: Christian Ludin, Manfred Keller
  • Patent number: 11235024
    Abstract: The present invention relates to pharmaceutical aerosols comprising a ?-hairpin peptidomimetic of formula cyclo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-), or a pharmaceutically acceptable salt thereof, having inhibitory activity against human neutrophil elastase. It further relates to solid or liquid pharmaceutical compositions and kits for preparing and administering such aerosols. The invention can be used for the prevention, management or treatment of pulmonary diseases, such as alpha-1 antitrypsin deficiency (AATD), cystic fibrosis (CF), non-cystic fibrosis bronchiactasis (NCFB), or chronic obstructive pulmonary disease (COPD), or infections, or diseases, or conditions of the lungs, being mediated by or resulting from human neutrophil elastase activity.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: February 1, 2022
    Assignee: POLYPHOR AG
    Inventors: Christian Ludin, Manfred Keller, Piet Bruijnzeel, Johann Zimmermann, Philip Barth, Eric Chevalier
  • Patent number: 11235025
    Abstract: The present invention relates to an Nkx3.2 fragment with improved stability under a histopathological environment of arthritis and to a pharmaceutical composition containing the same as an active ingredient. The Nkx3.2 fragment of the present invention has a function to activate NF-?B at the similar level to full-length Nkx3.2 and resistance to proteolysis by Siah1. In addition, the Nkx3.2 fragment exhibited at least a 10-fold improvement in degenerative arthritis treatment effect compared with Nkx3.2 in an animal model-based in vivo efficacy evaluation. Therefore, the Nkx3.2 fragment can be favorably used in the prevention or treatment of arthritis.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: February 1, 2022
    Assignee: ICM CO., LTD.
    Inventor: Dae-Won Kim
  • Patent number: 11235026
    Abstract: Disclosed herein are methods and compositions for modulating expression of a PD1 gene.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: February 1, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Michael C. Holmes, Matthew C. Mendel, Xiangdong Meng, David Paschon, Andreas Reik, Fyodor Urnov
  • Patent number: 11235027
    Abstract: Compositions and methods are provided for the generation or treatment of chronic tympanic membrane perforation by modulation of HB-EGF activity.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: February 1, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Peter Luke Santa Maria, Yunzhi Peter Yang, Sungwoo Kim, Chloe Domville-Lewis
  • Patent number: 11235028
    Abstract: The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-?B activity. The modulators may be used, for example, in the treatment of NF-?B-mediated diseases, conditions, and injuries.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: February 1, 2022
    Assignee: The Cleveland Clinic Foundation
    Inventor: Andrei V. Gudkov
  • Patent number: 11235029
    Abstract: The present invention relates to compositions and methods for the treatment of heart failure.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: February 1, 2022
    Assignees: Temple University-Of The Commonwealth System of Higher, Education Johns Hopkins Technology Ventures, Universita di Napoli Federico II
    Inventors: Alessandro Cannavo, Ning Feng, Giuseppe Rengo, Nazareno Paolocci, Walter J. Koch
  • Patent number: 11235030
    Abstract: Provided herein are compositions and methods for the treatment of tendinopathies, such as tenosynovitis, tendinosis or tendinitis, including Achilles tendinopathy, patellar tendinopathy, lateral epicondylitis or “tennis elbow,” medial epicondylitis or “golfer's elbow,” plantar fasciitis, and rotator cuff tendinopathy, and in particular to methods for the treatment of tendinopathies by administering compositions comprising platelet-derived growth factor (PDGF).
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: February 1, 2022
    Assignee: BioMimetic Therapeutics, LLC
    Inventors: Hans K. Kestler, Vivek Shah, Dean James Rager-Aguiar
  • Patent number: 11235031
    Abstract: The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: February 1, 2022
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony O. Caggiano, Anindita Ganguly, Jennifer Iaci, Tom Parry
  • Patent number: 11235032
    Abstract: The present disclosure provides a method of treating cancer with a priming dose of combination immunotherapy comprising IL-2 (e.g., extended-PK IL-2), an immune checkpoint inhibitor, a tumor targeting antibody or integrin-binding polypeptide, and optional cancer vaccine, administered prior to maintenance doses of immune checkpoint inhibitor therapy. The methods of the disclosure can be used to treat a broad range of cancer types.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: February 1, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Chensu Wang, Karl Dane Wittrup, Darrell J. Irvine
  • Patent number: 11235033
    Abstract: The subject invention provides molecules, compositions and methods for treating, preventing or ameliorating vascular calcification, for example, medial vascular calcification or intimal atherosclerotic calcification. The subject invention also provides molecules, compositions and methods for treating or preventing a disease associated with vascular calcification. The methods of the subject invention employ relaxin-based and/or epidermal growth factor receptor (EGFR)-based strategies through the use of RXFP1 agonists and/or EGFR inhibitors.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: February 1, 2022
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Joshua Hutcheson, Alexander Agoulnik, Hooi Hooi Ng
  • Patent number: 11235034
    Abstract: The present invention relates to the use of collagen hydrolysate for improving endurance performance by increasing mitochondrial activity. Further, the invention relates to the use of collagen hydrolysate for stimulating lipid catabolism, and in particular for reducing body weight, by increasing mitochondrial activity.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: February 1, 2022
    Assignee: GELITA AG
    Inventors: Steffen Oesser, Stephan Hausmanns, Hans-Ulrich Frech
  • Patent number: 11235035
    Abstract: A method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for improving nitrogen retention, or for improving dietary phosphorus absorption and retention, or for improving the efficacy of the phytase, or for improving the subject's resistance to necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for reducing populations of pathogenic bacteria in the gastrointestinal tract of a subject, or for reducing nutrient excretion in manure, which method comprising administering to a subject at least one direct fed microbial in combination with a phytase, wherein the phytase is administered to the subject at a dosage of more than about 1500 FTU/kg feed.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: February 1, 2022
    Inventors: Luis Romero, Peter Plumstead, Luke Barnard
  • Patent number: 11235036
    Abstract: Compositions and methods relating to potentially pathogenic mutations in the nucleotide sequence of a human LIPA gene. Some LIPA gene products have been discovered to be associated with reduced lysosomal acid lipase (LAL) activity.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: February 1, 2022
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Andrew Hutchinson, John V. W. Reynders, Guillermo del Angel, Nina Jain, Christen D. Forbes, Xiao-Qin Ren, Barbara Burton
  • Patent number: 11235037
    Abstract: The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20 (pegylated ADI derived from M. hominis), but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 1, 2022
    Assignee: Polaris Group
    Inventors: Robert Almassy, Richard E. Showalter, James A. Thomson, Wes Sisson, Wei-Jong Shia, Li-Chang Chen, Yang Lee
  • Patent number: 11235038
    Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: February 1, 2022
    Assignee: CUREMARK, LLC
    Inventor: Joan M. Fallon
  • Patent number: 11235039
    Abstract: The present disclosure provides for methods, systems, and compositions of nucleic acid and peptide sequences. The present disclosure provides for a nucleic acid sequence encoding two or more amino acid sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, and SEQ ID NO: 41.
    Type: Grant
    Filed: June 2, 2021
    Date of Patent: February 1, 2022
    Assignee: Think Therapeutics, Inc.
    Inventors: David Gifford, Brandon Carter
  • Patent number: 11235040
    Abstract: In one embodiment a vaccine composition comprises two or three AChR subunit constructs and an adjuvant. In some embodiments the AChR subunit construct is an AChR ?1 subunit construct, an AChR ?1 subunit construct, an AChR ? subunit construct, an AChR ? subunit construct, or an AChR ? subunit construct. In another embodiment, the invention provides a method of treating myasthenia gravis in a patient in need thereof, comprising administering a vaccine composition comprising one or more acetylcholine receptor subunit constructs selected from the group consisting of AChR ?1 subunit, AChR ?1 subunit, AChR ? subunit, AChR ? subunit, AChR ? subunit, a fragment thereof, and a combination thereof, and an adjuvant.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: February 1, 2022
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Jon Lindstrom, Jie Luo